Learn Treatment

Scale-Up of Direct-Acting Antiviral Treatment in Prisons is Both Cost-Effective and Key to HCV Elimination

The Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) study in Australia demonstrated that scaling-up of direct-acting antiviral treatment reduced hepatitis C virus (HCV) transmission.

A paper, published in Open Forum Infectious Diseases, evaluated the cost-effectiveness of scaling-up HCV treatment in state-wide prison services incorporating long-term outcomes across custodial and community settings. It showed that scaling-up HCV testing and treatment in prisons is highly cost-effective and should be considered a priority in the national elimination strategy.

The full paper can be accessed here.